Patient characteristics and risk factors of participants and non-participants in the NOR-COR study

Figures & data

Figure 1. Flow chart of the NOR-COR participation and non-participation study.

Table 1. Comparison of socio-demographic factors, clinical characteristics and risk factors between participants and non-participants.

	Participants n = 1127	Non-participants, n = 229	p-Value
Time since the index coronary event, months	17.1	17.3	ns
Mean age at the coronary event (SD), years	61.6 (9.6)	61.8 (10.4)	ns
Female, %	21.0	27.9	<0.05
Socio-demographic factors, %
Ethnic minorities^a, %	3.0	5.7	<0.05
Living alone, %	19.3	26.4	<0.05
Unemployed or on disability benefits, %	20.7	19.7	ns
Coronary diagnosis, %
Non ST elevation myocardial infarction	49.8	52.0	ns
ST elevation myocardial infarction	29.7	32.3	ns
Stable or unstable coronary heart disease	20.5	15.7	ns
Angiography findings, %
Open vessels	1.3	0.9	ns
Atherosclerosis, no sig. stenosis	4.8	3.1	ns
Singe-vessel disease	55.2	50.9	ns
Multi-vessel disease	38.6	45.1	ns
Coronary intervention, %
Percutaneous coronary intervention and stent	75.3	77.7	ns
Percutaneous coronary intervention without stent	2.0	0.9	ns
Coronary artery by-pass graft operation	13.0	10.9	ns
No intervention	9.6	10.5	ns
More than one coronary event, %	29.9	32.7	ns
Coronary risk factors, %
Current smoking	34.8	37.0	ns
Hypertension^b	43.4	54.4	<0.05
Diabetes type 1 and 2	16.6	23.8	<0.05
Participation in cardiac rehabilitation, %	50.1	27.5	<0.001

NS: non-significant; SD: standard deviation.

^a Ethnic minorities means 1st and 2nd generation patients from Asia, Africa and South America.

^b Hypertension noted in the hospital medical record.

Table 2. Comparison of somatic and psychiatric comorbidity and medication between participants and non-participants.

	Participants, n = 1127	Non-participants, n =  229	p-Value
Prevalence of somatic comorbidity, %
Heart failure	13.1	17.7	ns
Periphery vascular disease	8.9	11.6	ns
Apoplexy/transitory ischemic attacks	7.0	13.8	<0.01
Chronic obstructive pulmonary disease	8.8	11.0	ns
Chronic kidney failure^a	13.4	18.2	ns
Atrial fibrillation or atrial flutter	9.4	14.9	<0.05
Liver disease	3.1	3.0	ns
Charlson comorbidity score (SD)	4.1 (1.4)	4.4 (1.7)	<0.05
Prevalence of psychiatric comorbidity, % Depression	6.3	19.3	<0.001
Anxiety	3.0	8.9	<0.001
Medication at discharge, %
Aspirin	98.5	99.4	ns
Warfarin or NOAK’s	7.3	8.8	ns
Statins	96.1	98.3	ns
Betablockers	84.8	90.6	ns
Antidiabetics	10.9	14.4	ns
Insulin	4.3	8.3	<0.05
ACE-inhibitors	35.0	40.9	ns
Angiotensin-2-receptor blocker	20.3	21.0	ns
Aldosterone antagonists	2.8	3.9	ns
Nitrates	3.9	3.6	ns
Loop or tiazid diuretics	21.5	24.4	ns
Calcium channal blockers	16.1	13.8	ns
Psychotropic drugs (antidepressant or anxiolytics)	5.0	12.2	<0.001

NS: non-significant; SD: standard deviation; NOAC: novel anticoagulant drugs.

^a Defined as estimated glomerular filtration rate <60 mL/min/1,73m².

Table 3. Multi-adjusted odds ratio for not participating in the NORwegian CORonray Prevention Study.

	Odds ratio (95% confidence interval)
	Crude estimate	p-Value	Multi-adjusted estimate^a	p-Value
Age	2.7	ns	2.7	ns
Female sex	4.3 (2.9–7.5)	<0.05	2.1	ns
Ethnic minority background	7.0 (2.7–42.3)	<0.05	4.8	ns
Living alone	4.5 (2.9–8.4)	<0.05	3.6	ns
Charlson comorbidity score per unit	3.1 (2.8–3.6)	<0.05	3.4 (2.8–4.3)	<0.05
Anxiety	22.6 (5.4–321.8)	<0.001	5.1	ns
Depression	35.4 (9.9–254.2)	<0.001	14.5 (4.4–121.5)	0.001

NS: non-significant.

^a Adjusted for all other covariates.